http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Blastocystis species and Gastrointestinal Symptoms in Peruvian Adults Attended in a Public Hospital
Robles-Cabrera Mayra Ximena,Maguiña Jorge L.,Gonzales-Huerta Luis,Panduro-Correa Vicky,Dámaso-Mata Bernardo,Pecho-Silva Samuel,Navarro-Solsol Ana Claudia,Rabaan Ali A.,Rodríguez-Morales Alfonso J.,Art 대한감염학회 2021 Infection and Chemotherapy Vol.53 No.2
The objective of this study was to evaluate the role of Blastocystis sp. in gastrointestinal symptoms reported by adult patients in a Peruvian hospital. A case-control 3:1 study was performed at the outpatient clinic. Direct stool examinations were done. One hundred sixty patients were included, 40 cases and 120 controls. Positivity to Blastocystis sp. was associated with dyspepsia (P <0.001), bloating (P <0.001) and abdominal pain (P = 0.03) in patients attending our hospital outpatient clinic.
Recurrent malignant solitary fibrous tumor of the scalp: a case report and literature review
Ahmed Rabie,Abdulkarim Hasan,Yasein Mohammed,Ayman Abdelmaksoud,Rabaan Ali A. 대한병리학회 2022 Journal of Pathology and Translational Medicine Vol.56 No.2
Solitary fibrous tumor (SFT) is a rare type of mesenchymal neoplasm that first was discovered in the pleura but can also affect the peritoneum, lungs, mediastinum, and skin. Cutaneous malignant SFT is an extremely rare tumor that resembles dermatofibrosacoma protuberance (DFSP) histologically and immunohistochemically. Herein, we describe a case of malignant SFT that presented as a recurrent mass on the scalp. The first lesion was totally excised one year before recurrence and was diagnosed as a DFSP based on the histopathology and cluster of differentiation 34 immunostaining positivity. Re-examination of the previously examined specimen was considered. Activator of transcription 6 positivity was also detected in the tissue, confirming the diagnosis of a recurrent malignant SFT rather than DFSP. There was no evidence of recurrence, locoregional, or distant metastases at six months after lesion removal with a safety margin.